FDA approves AJOVY for paediatric migraine prevention
Teva’s CGRP therapy becomes first approved option for children and adolescent Teva’s CGRP therapy becomes first approved option for children and adolescent
Previous Post
Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial
Next Post
Avo and MEDITECH Partner to Integrate AI Scribe into Expanse EHR
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago